Intracranial Metastasis as the Initial Presentation of a Young Woman with Luminal B Her-2 Positive Stage 4 Breast Cancer

Santi Christiani Gultom, Amaylia Oehadian


Objective: Breast cancer is the second most common cause of brain metastasis (BM) among all of the solid cancers, with metastases occurring in 10%–16% of patients and in as many as 30% of autopsy studies. Breast cancer-related BM usually has a poor prognosis and survival rate in the absence of any treatment within 2 months. Survival after BM is related to the subtype of the primary tumor. Human epidermal growth factor-2 (HER-2)-positive patients have a significantly better prognosis compared with other subtypes. The prognosis for the majority of patients with BM remains poor, despite local and systemic therapies, with a median survival of around 10 months.

Methods: This case is interesting because our patient is very young, diagnosed with BM before breast cancer was identified, bit still surviving 12 months after her BM diagnosis. A 19-year old woman presented with seizures, vomit and headaches.

Results: A cranial CT-scan showed an intracranial mass. The intracranial tumor was removed, and yielded a histopathological result of metastatic adenocarcinoma. Further examination found a lump in her right breast. She was diagnosed with intracranial metastatic stage 4 luminal B Her 2(+) breast cancer. She was referred for WBRT, a mastectomy, chemotherapy with docetaxel cyclophosphamide 4 cycles, followed by 12 cycles of trastuzumab, and continued treatment with tamoxifen and goserelin. The last PET-Scan showed no residual disease.

Conclusion: Breast cancer as the primary tumor should be considered in women with a metastatic brain tumor. With appropriate treatment, even stage IV luminal B breast cancer with BM can still have a long life with good quality.


Breast cancer;brain metastasis; central nervous syste (CNS)

Full Text:



Cardoso F, Costa A, Norton L. ESO-ESMO 2nd International Consensus Guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25(10): 1871–88.

Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast. 2018;39:131–38.

Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. 2004;22(17):3608–17.

Lee Y-T. Breast carcinoma: Pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175–80.

Boogerd W, Vos VW, Hart AAM. Brain metastases in breast cancer; natural history, prognostic factors, and outcome. J Neuro Oncol. 1993;15:165–74

Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin. 2003;21(1):1-vii.

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21.

Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancermetastasis to the central nervous system. Am J Pathol. 2005;167:913–20.

Maurer C, Tulpin L, Moreau M, Dumitrescu C, Azambuja Ed, Paesmans P, et al. Risk factors for the development of brain metastases in patients with HER2positive breast cancer. ESMO Open. 2018;3:e000440.

Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys. 2003;55(5):1186–195.

Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–617.

Brufsky AM, Mayer M, Rugo HS, Tan CE, Tripathy D, Tudor IC, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–43.

Dawood S, Broglio K, Esteva FJ, Buzdar AU, Hortobagyi GN, Giordano HG. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19(7):1242–48.


Article Metrics

Abstract view : 329 times
PDF - 198 times


This Journal indexed by



Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

View My Stats